Immunome, Inc. (NASDAQ:IMNM) CEO Clay B. Siegall Purchases 150,000 Shares

Immunome, Inc. (NASDAQ:IMNM) CEO Clay B. Siegall bought 150,000 shares of the stock in a transaction that occurred on Friday, January 31st. The shares were purchased at an average price of $7.75 per share, for a total transaction of $1,162,500.00. Following the purchase, the chief executive officer now owns 669,636 shares in the company, valued at $5,189,679. This represents a 28.87 % increase in their position. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available at this link.

Immunome Stock Down 6.4 %

NASDAQ:IMNM opened at $10.32 on Tuesday. Immunome, Inc. has a 52 week low of $8.97 and a 52 week high of $30.96. The firm has a 50 day moving average of $11.34 and a 200 day moving average of $12.68. The stock has a market capitalization of $644.14 million, a price-to-earnings ratio of -1.27 and a beta of 1.90.

Analyst Ratings Changes

Several brokerages have commented on IMNM. Piper Sandler decreased their price target on shares of Immunome from $23.00 to $21.00 and set an “overweight” rating on the stock in a research note on Thursday, November 14th. Stephens began coverage on shares of Immunome in a research note on Friday, November 8th. They issued an “overweight” rating and a $30.00 price target on the stock. Finally, Wedbush reiterated an “outperform” rating and issued a $33.00 price target on shares of Immunome in a research note on Monday, January 13th. Five research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the company presently has a consensus rating of “Buy” and an average target price of $28.60.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently made changes to their positions in the stock. Stoneridge Investment Partners LLC purchased a new position in shares of Immunome in the fourth quarter worth $123,000. AQR Capital Management LLC raised its holdings in shares of Immunome by 34.6% in the second quarter. AQR Capital Management LLC now owns 16,064 shares of the company’s stock worth $194,000 after buying an additional 4,129 shares during the last quarter. Intech Investment Management LLC purchased a new position in shares of Immunome in the third quarter worth $219,000. Three Bridge Wealth Advisors LLC purchased a new position in shares of Immunome in the fourth quarter worth $293,000. Finally, JPMorgan Chase & Co. raised its holdings in shares of Immunome by 6.6% in the third quarter. JPMorgan Chase & Co. now owns 24,565 shares of the company’s stock worth $359,000 after buying an additional 1,520 shares during the last quarter. Hedge funds and other institutional investors own 44.58% of the company’s stock.

Immunome Company Profile

Immunome, Inc, a biotechnology company, develops targeted cancer therapies. The company's clinical asset comprises AL102, an investigational gamma secretase inhibitor currently in evaluation in a Phase 3 trial for the treatment of desmoid tumors; and preclinical assets consist of IM-1021, a receptor tyrosine kinase-like orphan receptor 1 and antibody-drug conjugates, as well as IM-3050, a fibroblast activation protein targeted radioligand therapy; and IM-4320, an anti-IL-38 immunotherapy candidate.